SignalChem Lifesciences, and a subsidiary of Merck, are evaluating the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe